Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia

Severe Hypoglycaemia Leading to Hospital Admission in Type 2 Diabetic Patients Aged 80 Years or Older

(2010) D. Greco et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients

(2010) Andreas Holstein et al.   Expert Opinion On Drug Safety

Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study

(2010) Craig J Currie et al.   LANCET

Loss-of-Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go-DARTS Study

(2009) K Zhou et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The E23K Variant ofKCNJ11and the Risk for Severe Sulfonylurea-induced Hypoglycemia in Patients with Type 2 Diabetes

(2009) A. Holstein et al.   HORMONE AND METABOLIC RESEARCH

Presence ofCYP2C9*3allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas

(2009) Georgia Ragia et al.   PHARMACOGENOMICS

Hypoglycaemia in Type 2 diabetes

(2008) S. A. Amiel et al.   DIABETIC MEDICINE

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE